Abstract

Acromegaly: Therapies and Benefits

Author(s): John Watson

Acromegaly, which is characterised by an excess of growth hormone, is accompanied with comorbidities that produce considerable clinical dysfunction and a high mortality risk. Late diagnosis, as well as poor therapy tolerance and adherence, impede outcomes. The purpose of this work is to give a scoping evaluation of the benefits of existing treatments and to describe potential constraints that may restrict disease control or treatment continuity. Current therapies include transsphenoidal surgery, which is frequently followed by the use of synthetic somatostatin analogues or growth hormone receptor antagonists. In the case of nonresponsive patients or recurrent tumours, radiotherapy is used as an adjuvant to treatment. Despite therapeutic benefits, patient burdens result in an estimated one-quarter of patients stopping treatment or going missing, with up to 88 percent of these cases having uncontrolled disease. Although early disease detection and rapid treatment improve disease outcomes, long-term treatment adherence is crucial to results. The most cost-efficient and effective solutions include a thorough grasp of the particular patient's condition and treatment loads, as well as the patient's knowledge of their disease and the full utilisation of all health care team resources.

The most cost-efficient and effective solutions include a thorough grasp of the particular patient's condition and treatment loads, as well as the patient's knowledge of their disease and the full utilisation of all health care team resources. Provider awareness of factors influencing follow-up, the use of precision medicine, and the implementation of a team approach that actively involves patients, nurses, and physicians in treatment decisions, location convenient disease monitoring with co-morbidity treatment coordination, and home drug administration are all important factors in facilitating long-term treatment adherence.